NASDAQ:XTLB

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

XTL Biopharmaceuticals logo
$1.58 +0.10 (+6.42%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About XTL Biopharmaceuticals Stock (NASDAQ:XTLB)

Advanced

Key Stats

Today's Range
$1.55
▼
$1.59
50-Day Range
$1.52
▼
$2.49
52-Week Range
$1.39
▼
$5.64
Volume
1,354 shs
Average Volume
609,238 shs
Market Capitalization
$3.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

XTL Biopharmaceuticals Ltd. is an Israel-based company listed on Nasdaq that has focused on developing and commercializing biopharmaceutical products. Its business strategy has also included acquiring and developing pharmaceutical and medical-device businesses.

Historically, the company pursued drug candidates for autoimmune diseases. Its research included hCDR1, an investigational peptide studied for systemic lupus erythematosus. These programs reflect its earlier development work and should not necessarily be understood as products currently marketed by the company.

AI Generated. May Contain Errors.

XTL Biopharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

XTLB MarketRank™: 
0.85716249656 of 5 stars

XTL Biopharmaceuticals scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    XTL Biopharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    XTL Biopharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about XTL Biopharmaceuticals' stock forecast and price target.
    • Percentage of Shares Shorted

      0.25% of the float of XTL Biopharmaceuticals has been sold short.
    • Short Interest Ratio / Days to Cover

      XTL Biopharmaceuticals has a short interest ratio ("days to cover") of 1.05, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in XTL Biopharmaceuticals has recently increased by 2.23%, indicating that investor sentiment is decreasing.
    • Dividend Yield

      XTL Biopharmaceuticals does not currently pay a dividend.

    • Dividend Growth

      XTL Biopharmaceuticals does not have a long track record of dividend growth.

    • News Sentiment

      XTL Biopharmaceuticals has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
    • News Coverage This Week

      MarketBeat has tracked 1 news article for XTL Biopharmaceuticals this week, compared to 1 article on an average week.
    • Insider Buying vs. Insider Selling

      In the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      29.00% of the stock of XTL Biopharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      4.40% of the stock of XTL Biopharmaceuticals is held by institutions.

    • Read more about XTL Biopharmaceuticals' insider trading history.
    Receive XTLB Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    XTLB Stock News Headlines

    Under 3 cents a night
    Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
    XTL Completed the Acquisition of Psyga Bio Ltd.
    See More Headlines

    XTLB Stock Analysis - Frequently Asked Questions

    XTL Biopharmaceuticals' stock was trading at $2.3040 on January 1st, 2026. Since then, XTLB shares have decreased by 34.2% and is now trading at $1.5150.

    XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) posted its quarterly earnings results on Wednesday, November, 18th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter.

    XTL Biopharmaceuticals shares reverse split on the morning of Wednesday, March 25th 2026.The 1-4 reverse split was announced on Friday, March 20th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 24th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

    Shares of XTLB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Company Calendar

    Last Earnings
    11/18/2026
    Today
    11/20/2026
    Fiscal Year End
    12/31/2026

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Biotechnology
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:XTLB
    CIK
    1023549
    Employees
    10
    Year Founded
    N/A

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    N/A
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    $450 thousand
    Price / Sales
    8.30
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($0.11) per share
    Price / Book
    -14.32

    Miscellaneous

    Outstanding Shares
    2,370,000
    Free Float
    1,680,000
    Market Cap
    $3.73 million
    Optionable
    Not Optionable
    Beta
    1.52
    7 Stocks That Could Lead the Next Market Boom Cover

    Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

    Get This Free Report

    This page (NASDAQ:XTLB) was last updated on 11/20/2026 by MarketBeat.com Staff.
    From Our Partners